RxDoctor Payments Data

Eric Arnett

Family · Owasso, OKNPI 1205235363

Payments from drug & device makers

$6,847in general payments, 2019–2025

Across 394 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$831
  • AbbVie$652
  • AstraZeneca$596
  • Lilly USA, LLC$595
  • GSK$415
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$6,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,847 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,017
Medicare patients
151
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$137,417
OzempicSemaglutide65$93,398
JardianceEmpagliflozin99$75,341
EliquisApixaban81$63,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$48,589
Dupixent SyringeDupilumab12$44,726
VraylarCariprazine Hcl16$24,533
XareltoRivaroxaban17$23,665
TrulicityDulaglutide20$23,248
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$22,919
EntrestoSacubitril/Valsartan21$22,122
LinzessLinaclotide16$19,505
FarxigaDapagliflozin Propanediol23$19,053
JanuviaSitagliptin Phosphate11$17,331
Synjardy XrEmpagliflozin/Metformin Hcl16$16,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$595$160,665127 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta$132$112,238142 claims
Novo NordiskOzempic$1,189$93,39865 claims
PfizerEliquis$831$63,92181 claims
GSKTrelegy Ellipta, Anoro Ellipta$415$56,40691 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$596$48,95169 claims
AbbVieVraylar, Linzess$652$44,03832 claims
Johnson & JohnsonXarelto$57$23,66517 claims
NovartisEntresto$61$22,12221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.

Other family in Owasso

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →